Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus…
CORRECTING and REPLACING Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy
Headline of release should read: Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy (instead of Santa Barbara Surgery Center is First in Southern California to Adopt New Wireless Technology for Arthroscopy) of release issued…
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023…
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata. LITFULO, a once-daily oral capsule, is the…
New vaccines enable pharmacies to become immunization destinations
For community pharmacists, cooler temperatures, school buses on the roads and Friday night football are not just signs of a changing season – they are indicators that patients will soon be seeking vaccinations for the 2023-2024 respiratory illness season. This…
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental new drug application (sNDA) seeking approval for WELIREG, Merck’s…
BrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer’s Prediction Biomarker
Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round. This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker…
Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions
Stryker (NYSE: SYK), one of the world’s leading medical technology companies, announced the launch of PROstep® MIS Lapidus, a new internal fixation system intended for treating bunions using a minimally invasive surgical reduction of hallux valgus deformity and subsequent fusion of…
ChoiceSpine® Announces Standalone Indication for Blackhawk® Ti 3D Printed Cervical Spacer System
ChoiceSpine LLC, a privately held spinal device company held by Altus Capital Partners in Knoxville, TN, is pleased to announce today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the Blackhawk® Ti 3D Printed…
Align Technology Connects With Over 1,000 Doctors and Practice Staff at the 2023 Invisalign™ GP Summit Where Leaders in Digital Orthodontics and Restorative Dentistry Share Best Practices for Leading Transformation in Dentistry
Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from…
PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery…
ChromaTan™ Appoints Dr. Rajiv Datar as New CEO
ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company. A bioentrepreneur with over 25 years C-level experience in bioprocessing and drug development, Dr. Datar succeeds Oleg Shinkazh, the Founder of ChromaTan, who…